A Phase 2 interventional study of Liposomal Alendronate and Liposomal Alendronate in Coronary Artery Stenosis, sponsored by BIOrest Ltd.. Completed at 12 sites in Israel. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-01-20.
Sponsored by BIOrest Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Coronary Stenosis with a site in Israel — none open to participants now, 2 under way, 1 of them phase 3. Coronary Stenosis · Israel.
Among the 15 studies in Coronary Stenosis with a site in Israel, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2, and was the 4th registered.
326 studies on the registry are indexed under Coronary Stenosis; 57 are open to participants now.
Browse Coronary Stenosis studies →None of the 15 studies in Coronary Stenosis with a site in Israel is open now. The open studies under Coronary Stenosis, anywhere →
Of the 40 Coronary Stenosis studies recruiting now, 33 (83%) set no upper age limit and 3 (8%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2008.
This study's enrollment of 226 is above the median of 190 across 191 interventional studies indexed under Coronary Stenosis.
Median enrollment 812 across the 11 interventional studies, 128 across the 3 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 7 most frequent:
BIOrest Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
BIOrest Ltd. has 1 study filed under Coronary Stenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Coronary Stenosis with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare metal stent.
Study hypothesis: Liposomal Alendronate will reduce in-stent restenosis as compared to placebo.
This is a Phase II dose-finding, randomized, multi-center, prospective, double blind clinical study. Subjects undergoing percutaneous coronary intervention (PCI) with the Presillion™ CoCr bare metal stent will be randomized into three groups and administered (in a single dose intravenously (IV) through a peripheral venous catheter) either: low dose Liposomal Alendronate of 0.001 mg, high dose Liposomal Alendronate of 0.01 mg, or placebo (IV saline infusion) on a 1:1:1 basis.
All subjects will undergo angiographic follow-up at 6 months and 110 subjects enrolled from pre-specified sites will undergo intravascular ultrasound (IVUS) at baseline and follow-up at 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
General
Angiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liposomal Alendronate dose of 0.001 mg
Drug: Liposomal Alendronate
Liposomal Alendronate dose of 0.01 mg
Drug: Liposomal Alendronate
IV saline infusion
Drug: Saline infusion (placebo)
IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
Also known as: LA
IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
Also known as: LA
IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
Also known as: Saline
In-stent late loss: measured at 6 months post-procedure as determined by quantitative coronary angiography (QCA).
Time frame: 6 months post-procedure
Major Adverse Cardiac Events (MACE)
Time frame: at 30, 180 and 360 days as well as yearly through 5 years post-procedure
The record gives a start of Sep 2008, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alendronate
BIOrest Ltd.